LONDON: Scancell Holdings plc (AIM: SCLP), a developer of cancer immunotherapies, has appointed Dr. Phil L’Huillier as the new Chief Executive Officer, effective November 18, 2024. Dr. L’Huillier, previously CEO of CatalYm GmbH, brings extensive experience in expanding investor bases and progressing clinical studies. Professor Lindy Durrant, the current CEO, will remain in her role…